The WHO Declared Ebola A Public Health Emergency Of International Concern.

On May 17, 2026, in Geneva, Switzerland, the Director-General of the World Health Organization (WHO), pursuant to Article 12 of the International Health Regulations (2005), officially declared the Ebola outbreak caused by the Bundibugyo strain in the Democratic Republic of Congo and Uganda a Public Health Emergency of International Concern (PHEIC). This marks the third time the WHO has issued a global public health alert of the highest level for Ebola, and it is one of the most severe viral hemorrhagic fever crises faced by the African region in the past decade. As of May 24, the DRC had reported a cumulative total of 867 suspected cases and 204 deaths, while Uganda had reported 5 confirmed cases, with the risk of cross-border transmission continuing to rise. The core characteristics of this outbreak are the lack of an approved vaccine, the absence of specific treatments, early covert transmission, and instability in the affected areas. These multiple factors combined have made prevention and control far more difficult than ever before, posing a severe test to the global public health system.

Rare strains and multiple crises have put prevention and control in a passive position.

This Ebola outbreak was not caused by the common Zaire strain, but by the Bundibugyo strain-a rare, highly lethal strain with a lack of targeted medical treatment. Its historical case fatality rate is approximately 30%-50%, reaching as high as 90%, meaning that on average, one in two infected individuals dies. Compared to the 2014 West African Ebola outbreak and the 2018-2020 Democratic Republic of Congo Ebola outbreak, this outbreak exhibits four key characteristics, leading to its rapid spread upon discovery and severely hindering control efforts.

 

(i) The strain is rare and there is no specific drug; medical intervention is almost non-existent.

The Bundibugyo strain of Ebola virus was first discovered in the Bundibugyo region of the Democratic Republic of Congo in 2007. It caused a small-scale outbreak in Uganda in 2012 and remained in a low-activity state for many years afterward. Unlike the Zaire strain of Ebola, there is currently no approved vaccine or specific treatment for the Bundibugyo strain globally. Existing medical treatments can only provide supportive care, such as fluid replacement, maintaining electrolyte balance, and managing complications; they cannot fundamentally suppress viral replication or eliminate the virus from the body. Experts from the World Health Organization have stated that due to the rarity of the strain, global medical research and development resources are severely insufficient, and related vaccines and drugs are still in the preclinical research stage, unlikely to be available in the short term. This means that once an infected person is diagnosed, they can only rely on their own immune system to fight the virus, with extremely limited medical intervention effects, significantly increasing the risk of death.

 

(II) Early covert transmission for 11 days, the golden period for prevention and control was completely missed.

The first suspected case of this outbreak occurred on April 24, 2026, in Ituri Province, Democratic Republic of Congo. However, local officials did not receive the first outbreak alert until May 5, a full 11 days later. During this 11-day "silent period," the virus went undetected and spread silently within the community through close contact, leading to a continuous increase in infections and a prolonged transmission chain. More critically, the testing equipment in Ituri Province could only identify the most common Zaire strain of Ebola. Early test results for all samples were negative, leading medical staff to misdiagnose it as common malaria or influenza, further delaying control efforts. It wasn't until the samples were sent to the capital, Kinshasa, hundreds of miles away, that a rare Bundibugyo strain of Ebola was finally confirmed, wasting another week of crucial control time. The WHO assessment concluded that when the outbreak was discovered, the actual number of infections far exceeded the reported number, and the concealed transmission made it difficult to accurately trace the spread of the epidemic, exponentially increasing the difficulty of subsequent control efforts.

(III) The situation in the epidemic area is turbulent, and the medical system is on the verge of collapse.

The Ituri and North Kivu provinces in the Democratic Republic of Congo, the hardest-hit areas in this wave of the epidemic, are regions in the country's eastern part that have long been plagued by conflict, with anti-government armed groups entrenched and the situation remaining volatile. The conflict has led to severe shortages of local medical facilities, insufficient medical personnel, and an extreme lack of medical supplies. Many hospitals and clinics have been forced to close, and the remaining medical institutions lack basic protective equipment and testing capabilities. Simultaneously, the armed conflict has resulted in frequent population movement, with people in the affected areas constantly migrating to escape the fighting, further accelerating the cross-border and cross-regional spread of the virus. Even more worrying is the fact that four medical personnel have died from Ebola, raising serious concerns about nosocomial transmission and exacerbating panic among local medical staff. Some medical personnel have refused to work, pushing the healthcare system to the brink of collapse. Furthermore, the severe humanitarian crisis in the conflict-ridden areas, with people lacking basic clean water and sanitation, significantly increases the risk of close contact transmission, providing a breeding ground for the virus.

 

(iv) Cross-border transmission has become a reality, and the risk of urban spread has increased dramatically.

As the pandemic continues to evolve, cross-border transmission has transformed from a potential risk into a real threat. On May 16, Kinshasa, the capital of the Democratic Republic of Congo, reported one confirmed case of a person returning from Ituri Province; on the same day, Kampala, the capital of Uganda, reported two imported cases from the DRC, one of whom died. On May 23, Uganda reported its first two locally transmitted cases: the driver who transported the first patient and a medical worker who cared for the first patient, marking the beginning of local transmission within Uganda. The WHO emphasizes that the emergence of cases in major cities like Kinshasa and Kampala indicates that the pandemic has spread from remote rural areas to densely populated cities, and sustained transmission in urban communities could have catastrophic consequences. Furthermore, the DRC has frequent border trade and close personnel exchanges with Uganda, Rwanda, Burundi, and other countries, making border control extremely difficult and posing a very high risk of further spread of the pandemic to other African countries.

Multiple countries coordinated emergency deployments, and China strengthened its defenses against imported cases.

Following the WHO's declaration of the current Ebola outbreak as a Public Health Emergency of International Concern (PHEIC), the world swiftly activated its highest-level public health response mechanism. The WHO spearheaded the coordination of international resources, with many African countries upgrading their prevention and control measures. China, the United States, the European Union, and other countries and regions simultaneously issued travel warnings and strengthened entry quarantine measures, launching a comprehensive global effort to combat Ebola.

 

As the core coordinating body in global public health, the WHO convened an emergency committee immediately after declaring a PHEIC, formulating and issuing interim prevention and control recommendations to guide countries worldwide in their prevention and control efforts. The WHO's core measures include: first, urgently dispatching expert teams to the affected areas to assist the Democratic Republic of Congo and Uganda in case surveillance, contact tracing, sample testing, and infection control; second, coordinating global donations of medical supplies, prioritizing the allocation of critical materials such as personal protective equipment (PPE), testing reagents, and intravenous fluids to the affected areas to alleviate local medical resource shortages; third, strengthening risk communication, regularly releasing the latest epidemic data, transmission routes, and prevention and control knowledge to eliminate public panic and guide the public in taking personal protective measures; and fourth, launching a green channel for vaccine development, collaborating with top global research institutions to accelerate the development of a Bundibugyo Ebola vaccine, striving to enter the clinical trial stage as soon as possible. At the same time, the WHO clearly assesses that the current outbreak poses an extremely high risk at the national and regional levels, but a low risk globally, and has not yet met the criteria for a "pandemic emergency." The WHO calls on the international community to respond rationally and avoid excessive panic and unnecessary travel restrictions.

 

Faced with the severe epidemic situation, African countries have acted swiftly, upgrading their prevention and control measures and strengthening regional defenses. The government of the Democratic Republic of Congo (DRC) declared a nationwide public health emergency, suspending all passenger flights at Bunia Airport, the hardest-hit area, closing some border crossings, restricting the movement of people from affected areas, and mobilizing the military to assist in maintaining order and ensuring the transport of medical supplies. The Ugandan Ministry of Health established a National Ebola Task Force, implementing strict controls on the capital Kampala and border regions, conducting temperature checks and health declarations for all inbound travelers, and imposing mandatory quarantine and medical observation on close contacts of confirmed cases. Neighboring countries such as Rwanda, Burundi, and Kenya simultaneously strengthened border quarantine, suspended non-essential travel with the DRC and Uganda affected areas, and conducted Ebola prevention and control awareness campaigns to raise public awareness. The Africa Centres for Disease Control and Prevention (Africa CDC) urgently activated a regional emergency response, coordinating the sharing of epidemic data, medical resources, and prevention and control experience among African countries to help affected countries improve their prevention and control capabilities.

 

As a key participant in global public health security, China attaches great importance to the risk of imported Ebola cases. The General Administration of Customs, the National Center for Disease Control and Prevention, the Ministry of Foreign Affairs, and other departments have worked together to quickly introduce a series of prevention and control measures, comprehensively strengthening the defense against imported cases. Core prevention and control measures include: First, issuing travel warnings, reminding Chinese citizens not to travel to countries and regions with high epidemic risks, such as the Democratic Republic of Congo and Uganda, unless absolutely necessary. If travel is necessary, personal protection measures must be taken to avoid contact with wild animals and suspected infected persons. Second, strengthening entry quarantine, with customs at all ports of entry across the country strictly implementing temperature monitoring, health declaration, symptom screening, and nucleic acid testing for inbound personnel from countries and regions with high epidemic risks. Those with suspicious symptoms such as fever, fatigue, headache, vomiting, or unexplained bleeding will be immediately isolated and transferred to medical institutions for treatment. Third, implementing health monitoring, requiring personnel arriving in (or returning to) China from countries and regions with high epidemic risks to undergo 21 days of health monitoring from the date of entry. Self-monitoring of health is crucial. If suspicious symptoms appear, seek medical attention promptly and proactively disclose any overseas travel history. Fourthly, emergency preparedness is essential. Medical and health institutions at all levels should strengthen training in Ebola case diagnosis and treatment, stockpile sufficient protective equipment and treatment drugs, and improve emergency plans for the entire process of case discovery, reporting, isolation, and treatment to ensure rapid response and strict prevention of spread should imported cases be detected. Fifthly, international cooperation should be strengthened. China actively responded to the WHO's call, providing medical supplies to countries in the affected areas such as the Democratic Republic of Congo and Uganda, and dispatching public health experts to assist local prevention and control efforts, demonstrating its responsibility as a major power.

 

In addition to China, the United States, the European Union, the United Kingdom, Japan, and other countries and regions also quickly issued travel warnings, strengthened entry quarantine, and restricted the movement of people and goods from affected areas. Meanwhile, global pharmaceutical companies and research institutions are taking action to accelerate the development of vaccines and drugs for the Bundibugyo type of Ebola, with some companies already initiating preparations for clinical trials. International humanitarian organizations such as the International Red Cross and Doctors Without Borders have dispatched medical volunteers to affected areas, set up temporary isolation wards and testing laboratories, and provided basic medical services to the affected population. Global financial institutions have also increased their financial assistance to countries affected by the pandemic, helping local governments improve their healthcare systems and carry out pandemic prevention and control efforts. Thanks to global efforts, the cross-border spread of this wave of the pandemic has been initially contained. However, due to the unstable situation and scarcity of medical resources in affected areas, the pandemic prevention and control situation remains severe, and the international community still needs to continue its efforts and coordinate its response.

Addressing shortcomings and strengthening global collaboration

One of the core lessons of this pandemic is that rare strains led to early misdiagnosis and missed diagnoses, resulting in missed opportunities for optimal prevention and control. Currently, global disease surveillance systems primarily focus on common infectious diseases, with severely insufficient capacity to monitor rare strains and emerging variants, especially in regions with underdeveloped medical systems like Africa, where testing equipment is scarce and technology is rudimentary, making rapid identification of rare pathogens difficult. In the future, the international community needs to increase investment in rare disease surveillance and early warning systems. This includes: first, promoting the deployment of testing equipment to high-risk areas such as Africa and Southeast Asia, equipping them with multifunctional, rapid testing devices to improve local rare pathogen identification capabilities; second, establishing a global rare disease database to integrate rare disease epidemic data, strain gene sequences, and clinical treatment experiences from various countries, enabling global data sharing and real-time early warning; and third, strengthening training for primary healthcare workers to improve their ability to identify, diagnose, and report rare infectious diseases, ensuring timely detection and rapid response in the early stages of an outbreak.

The lack of approved vaccines and effective drugs in this pandemic has fully exposed the uneven distribution of global pharmaceutical research and development resources and the insufficient investment in rare disease research. For a long time, global pharmaceutical companies have tended to invest in the research and development of common diseases and high-profit drugs, showing less enthusiasm for the research and development of rare infectious diseases and diseases prevalent in remote areas, resulting in a long-term lack of related vaccines and drugs. In the future, the international community needs to strengthen global pharmaceutical research and development collaboration. First, a special public health research and development fund should be established, jointly funded by governments, international organizations, and pharmaceutical companies, specifically for the research and development of vaccines and drugs for rare infectious diseases and emerging infectious diseases, ensuring stable investment in research funds. Second, open sharing of scientific research resources should be promoted, breaking down technical barriers between countries, companies, and institutions, encouraging global researchers to conduct joint research and development work, and accelerating the research and development process. Third, research and development incentive mechanisms should be improved, providing policy support, financial rewards, patent protection, and other preferential treatment to companies and institutions that develop vaccines or effective drugs for rare infectious diseases, mobilizing the enthusiasm of all parties for research and development. Fourth, a vaccine and drug reserve should be established, strategically stockpiling successfully developed vaccines and drugs for rare infectious diseases to ensure rapid allocation and timely use in the event of an outbreak.

 

The eastern Democratic Republic of Congo, the hardest-hit region in this round of the epidemic, has long suffered from war and instability, leading to the collapse of its medical system, disorderly population movement, and difficulties in implementing prevention and control measures, becoming a major driving force for the continued spread of the epidemic. Currently, the global public health governance system lacks effective mechanisms for responding to epidemic prevention and control in volatile and conflict-ridden regions, making it difficult to coordinate the efforts of all parties to carry out collaborative prevention and control. In the future, the international community needs to improve regional collaborative governance mechanisms. First, it should promote consensus among conflicting parties on health security, establishing "health security corridors" in war-torn areas to ensure the normal operation of medical supply transportation, medical personnel movement, and patient transfer. Second, it should leverage the core role of regional organizations, strengthening the coordination capacity of regional organizations such as the Africa Centres for Disease Control and Prevention (Africa CDC) and the East African Community (EAC), promoting the sharing of epidemic data, medical resources, and prevention and control experience among countries within the region, and jointly carrying out border control, case tracing, and isolation treatment. Third, it should increase support for the reconstruction of medical systems in volatile regions. The international community needs to provide long-term medical assistance to volatile regions such as the Democratic Republic of Congo, Yemen, and Afghanistan to help rebuild hospitals and clinics, train medical personnel, and improve medical facilities, fundamentally enhancing local epidemic prevention and control capabilities.

 

The current Ebola outbreak once again demonstrates that infectious diseases know no borders, and public health security is a common challenge for all humanity. No country can remain unaffected; only by deepening global cooperation and collaborative prevention and control can we effectively address the threat of epidemics. Currently, geographical, informational, and resource barriers persist in the global public health field. Some countries, adhering to a "national priority" mentality, have adopted unilateralist measures in pandemic prevention and control, hindering the global collaborative prevention and control process. In the future, the international community needs to abandon unilateralism and narrow nationalism, and deepen global public health cooperation. First, it is crucial to uphold the WHO's core coordinating role; all countries must actively cooperate with the WHO, strictly abide by the International Health Regulations, implement the WHO's prevention and control recommendations, and jointly maintain global public health order. Second, it is essential to promote the equitable distribution of global public health resources; developed countries need to assume greater responsibility, increasing medical assistance, technical support, and personnel training for developing countries and underdeveloped regions to narrow global healthcare gaps. Third, it is vital to strengthen coordination in international travel and trade controls; countries need to adopt appropriate and precise travel and trade restrictions based on scientific assessments to avoid excessive restrictions that could lead to global economic stagnation and exacerbate humanitarian crises. Fourth, it is necessary to build a global public health emergency response network, establishing transnational and transregional mechanisms for emergency material allocation, expert support, and case transfer to ensure rapid response and coordinated handling in the event of an outbreak.

Conclusion

The World Health Organization (WHO) declared the current Bundibugyo Ebola outbreak a Public Health Emergency of International Concern (PHEIC), a statement that reflects both the objective assessment of the severity of the situation and a comprehensive test for the global public health system. The rare strain, its insidious transmission, the volatile situation, and cross-border spread-multiple crises combined mean that controlling this Ebola outbreak is destined to be long and arduous. However, it is encouraging that the world has swiftly activated its highest-level response mechanism. With the WHO coordinating efforts, African countries actively responding, China strengthening its defenses against imported cases, and the international community providing collaborative support, a global battle to safeguard human health and safety is underway.

Currently, epidemic prevention and control remains at a critical stage. The global public health system needs to learn from this outbreak, deeply reflect on its shortcomings and deficiencies, accelerate the improvement of rare disease monitoring and early warning systems, strengthen global collaborative drug research and development, improve regional collaborative governance mechanisms, and deepen global public health cooperation to fundamentally enhance the world's ability to respond to emerging infectious diseases.

Infectious diseases know no borders; solidarity is the only way to defeat the epidemic. In the face of the ongoing Ebola outbreak, the international community needs to set aside its differences, join hands, rely on science, be driven by cooperation, and take responsibility to jointly build a strong global public health security defense line, safeguard the lives and health of people around the world, promote the building of a global community of health for all, and ensure that the virus no longer poses a common threat to humanity.

Disclaimer: The information published on this website is sourced from the internet and does not represent the views of this website, nor does it guarantee the accuracy of its content. Please be aware of the distinction. Furthermore, the products provided by our company are for scientific research purposes only. We are not responsible for any consequences arising from improper use. If you are interested in our products, have any criticisms or suggestions regarding our articles, or are not completely satisfied with the products you received, please contact us by email: allen@faithfulbio.com; our team is dedicated to ensuring complete customer satisfaction.